Live Terminal
Telegram

Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
📊
Market & Financial Impact: Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upside from the current market price. The brokerage expects the drugmaker’s shift from its traditional anti-retroviral (ARV) business towards contract development and manufacturing (CDMO) to drive its next phase of growth.
💡
Actionable Insight: 🟢 Bullish Trigger: Positive business expansion or earnings beat may attract institutional and retail buying.

Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

US mid-term elections – Part 2: What does it mean for Trump to lose control of Congress?

The ABCD of the US mid-term elections – Part 1: Why it matters across the globe

📰
Official Publisher Attribution: This report is aggregated from Economic Times. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on Economic Times ↗
⚡
Get Breaking Stock Alerts & Q-Results on Telegram
Real-time 1200x675 image cards and financial filings delivered instantly.
Join @Zerolive_news ↗
Link copied to clipboard! ✅